GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Egetis Therapeutics AB (LTS:0ABW) » Definitions » Research & Development

Egetis Therapeutics AB (LTS:0ABW) Research & Development : kr143.80 Mil (TTM As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Egetis Therapeutics AB Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Egetis Therapeutics AB's Research & Development for the three months ended in Mar. 2025 was kr30.50 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 was kr143.80 Mil.

Egetis Therapeutics AB Research & Development Historical Data

The historical data trend for Egetis Therapeutics AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egetis Therapeutics AB Research & Development Chart

Egetis Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 194.00 146.20

Egetis Therapeutics AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 32.80 40.10 32.20 41.00 30.50

Egetis Therapeutics AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr143.80 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Egetis Therapeutics AB  (LTS:0ABW) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Egetis Therapeutics AB Research & Development Related Terms

Thank you for viewing the detailed overview of Egetis Therapeutics AB's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Egetis Therapeutics AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Egetis Therapeutics AB (LTS:0ABW) » Definitions » Research & Development
Comparable Companies
OSTO:GENO OSTO:XSPRAY OSTO:VICO OSTO:SANION OSTO:HNSA OSTO:SYNACT OSTO:BINV OSTO:DMYD B XSAT:HAMLET B OSTO:IBT B VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
EGTX:Sweden P0F:Germany
Address
Grev Turegatan 11 C, Stockholm, SWE, 114 46
Website
https://www.egetis.com
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.

Egetis Therapeutics AB Headlines

No Headlines